CLINICAL TRIALS PROFILE FOR DIETHYLCARBAMAZINE CITRATE
✉ Email this page to a colleague
All Clinical Trials for DIETHYLCARBAMAZINE CITRATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01111305 ↗ | Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 2010-04-01 | Diethylcarbamazine citrate (DEC) treatment of Loa loa infection is complicated by the development of severe adverse reactions that are correlated with the number of circulating microfilariae in the blood. The cause of these reactions is unknown, but they are accompanied by a dramatic interleukin-5 (IL-5)-dependent increase in eosinophilia and evidence of eosinophil activation. This randomized, placebo-controlled, double-blind pilot study (conducted at the NIH Clinical Center) will assess whether and to what extent the administration of reslizumab (Cinquil ), a humanized monoclonal antibody directed against IL-5, given 3 to 7 days before administration of the anthelminthic drug DEC (at 3 mg/kg 3 times daily for 21 days), prevents the development of eosinophilia in 10 adult subjects with Loa loa infection and 0-5000 microfilariae/mL. Secondary outcomes will include the severity of post-treatment effects, markers of eosinophil activation, and effects of reslizumab on microfilarial clearance. |
| NCT01593722 ↗ | Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 | 2012-04-01 | Background: - Loa loa is a small worm that infects people in West and Central Africa. It is spread by the bite of a fly. Adult worms live under the skin and can cause swelling in the arms, legs, and face. Some people have more serious infections in the heart, kidneys, or brain. Most people with Loa loa infection have no symptoms at all. The standard treatment for Loa loa infection is a medicine called diethylcarbamazine (DEC). Some people have bad reactions to DEC, including itching, muscle pains, and in severe cases coma and death. - Another drug, ivermectin, is used in mass drug treatment programs to prevent the spread of worm infections that cause blindness and massive swelling (elephantiasis). However, people who also have Loa loa have had serious bad reactions to ivermectin. Researchers want to study both DEC and ivermectin to find out why these reactions occur. If they can be prevented, mass drug treatment programs will be able to be used in areas in Africa where Loa loa exists. Objectives: - To study the side effects of DEC and ivermectin treatment for Loa loa infection. Eligibility: - Individuals who live in 4 villages in Cameroon where Loa loa infection is known to exist, who are between 20 and 60 years of age, not pregnant or breastfeeding and have a low level of Loa loa parasites in the blood, but are otherwise healthy. Design: - Participants will be screened with a physical exam and medical history. Blood samples will be collected to check for Loa loa infection. Participants will also have an eye exam and provide skin samples to check for other worm infections that may interfere with the study treatment. - Participants will be admitted to the hospital for 4 days (during and after the treatment). They will receive a single dose of either DEC or ivermectin. - After treatment, regular blood samples will be collected. Participants will be asked questions about how they feel after treatment. Physical exams will be performed. If side effects develop, participants will be treated at the hospital. - After leaving the hospital, participants will have followup visits. These visits will happen on days 5, 7, 9, and 14 after receiving the study medicine. They will involve a short physical exam and collection of blood samples. - At the end of the study, participants will be offered a full 21-day DEC treatment to cure the Loa loa infection. |
| NCT04410406 ↗ | Moxidectin for LF, Cote d'Ivoire (DOLF) | Enrolling by invitation | Case Western Reserve University | Phase 3 | 2020-08-20 | The purpose of this study is to determine whether moxidectin (Mox) will be more effective than ivermectin (IVM) when used in single-dose combination therapies for lymphatic filariasis (LF). |
| NCT04410406 ↗ | Moxidectin for LF, Cote d'Ivoire (DOLF) | Enrolling by invitation | Regional Hospital of Agboville, Southern Cote d'Ivoire | Phase 3 | 2020-08-20 | The purpose of this study is to determine whether moxidectin (Mox) will be more effective than ivermectin (IVM) when used in single-dose combination therapies for lymphatic filariasis (LF). |
| NCT04410406 ↗ | Moxidectin for LF, Cote d'Ivoire (DOLF) | Enrolling by invitation | Washington University School of Medicine | Phase 3 | 2020-08-20 | The purpose of this study is to determine whether moxidectin (Mox) will be more effective than ivermectin (IVM) when used in single-dose combination therapies for lymphatic filariasis (LF). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DIETHYLCARBAMAZINE CITRATE
Condition Name
Clinical Trial Locations for DIETHYLCARBAMAZINE CITRATE
Trials by Country
Clinical Trial Progress for DIETHYLCARBAMAZINE CITRATE
Clinical Trial Phase
Clinical Trial Sponsors for DIETHYLCARBAMAZINE CITRATE
Sponsor Name
| Sponsor Name for DIETHYLCARBAMAZINE CITRATE | |
| Sponsor | Trials |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| Case Western Reserve University | 1 |
| Regional Hospital of Agboville, Southern Cote d'Ivoire | 1 |
| [disabled in preview] | 1 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
